Peptide Vaccine: Progress and Challenges

Peptide Vaccine: Progress and Challenges

Conventional vaccine strategies have been highly efficacious for several decades in reducing mortality and morbidity due to infectious diseases. The bane of conventional vaccines, such as those that include whole organisms or large proteins, appear to be the inclusion of unnecessary antigenic load that, not only contributes little to the protective immune response, but complicates the situation...

Progress and challenges in TB vaccine development

The Bacille Calmette Guerin (BCG) vaccine can provide decades of protection against tuberculosis (TB) disease, and although imperfect, BCG is proof that vaccine mediated protection against TB is a possibility. A new TB vaccine is, therefore, an inevitability; the question is how long will it take us to get there? We have made substantial progress in the development of vaccine platforms, in the ...

HIV Vaccine development: Challenges and Progress

Currently 33.3 million people are estimated to be infected with HIV, with 2.6 million new infections occurring in 2009 alone (1). As we enter the fourth decade of the HIV epidemic, UNAIDS vision calls for zero discrimination, zero new HIV infections and zero AIDS related deaths through universal access to effective HIV prevention, treatment, care and support. Access to antiretroviral therapy (A...

Dengue Vaccine: The Need, the Challenges, and Progress.

Developing a dengue vaccine: progress and future challenges.

Dengue is an expanding public health problem in the tropics and subtropical areas. Millions of people, most from resource-constrained countries, seek treatment every year for dengue-related disease. Despite more than 70 years of effort, a safe and efficacious vaccine remains unavailable. Antidengue antiviral drugs also do not exist despite attempts to develop or repurpose drug compounds. Gaps i...